The SNIIR-AM, a nation-wide, population-based database, records anonymized individual data on all reimbursements for health care utilization that have been provided by health-care professionals, including drugs, outpatient medical and nursing care. There is no direct information on the medical indication of reimbursements, but the SNIIR-AM includes information on long-term disease status (LTD status) that allows patients to receive treatment for severe and costly conditions without advancing payment. SNIIR-AM also contains information on free-accessto-care status that enables patients of lower socioeconomic status to receive free medical care. Information from the SNIIR-AM database are cross-referenced with the French hospital discharge database (Programme de Médicalisation des Systèmes d'Information, PMSI) that provides medical information about all patients admitted to hospital in France, including discharge diagnoses coded using ICD-10, medical procedures, and French diagnosis-related groups. The Echantillon Généraliste de Bénéficiaires (EGB) database is a random sample of 1 on 97 individuals covered by the SNIIR-AM. The objective is: How to identify these patients (likely to have osteoporosis or CIRD diseases) within the French claims database, to then run analyses.
METHODS:
As there is no diagnosis code in the database, treatment pattern or medical resource utilization could be used to identify patients.
Patients with osteoporosis has been identified in EGB database with age (≥50), and reimbursement of any anti-osteoporotic agents in the database (ATC codes), or osteoporosis-related hospitalization, or Long Term Disease (LTD) status, based on ICD-10 code.
For CIRD diseases, the study population includes 3 sub-groups, identified in the SNIIR-AM database: patients with RA, PA and AS. 
RESULTS:
Identification criteria for osteoporosis allowed us to identify 7,939 patients, corresponding to 4.5% of the French population ≥50 years. This population consists of 92% of women and means age is 71.6 years.
These study shown little overlap among the criteria. Patients have been mostly identified by anti-osteoporotic drugs (88%).
Identification criteria selected 233,304 for RA, 118,139 patients for SA and 34,052 patients for RP, corresponding to 0.62% of French population. 
